Chapter 29

Which of the following agents has not shown effectiveness in the prophylactic treatment of migraine headache? (A) zolmitriptan (B) valproic acid (C) verapamil (D) naproxen (E) amitriptyline

Use of sumatriptan is contraindicated in which one of the following groups of patients? (A) postpartum women (B) patients with uncontrolled hypertension (C) patients with moderate to severe unresponsive migraines (D) patients with hepatic insufficiency (E) patients with renal dysfunction

The therapeutic effect of the triptan class of drugs is caused by which mechanism of action? (A) antagonism at serotonin 5- \(\mathrm{HT}_2\) receptors (B) stimulation of serotonin \(5-\mathrm{HT}_{1 \mathrm{D}}^2\) receptors (C) antagonism at dopamine receptors (D) antagonism at \(\alpha\)-adrenoceptors (E) direct inhibition of substance \(\mathrm{P}\) receptors in the vasculature

Verapamil is indicated for the treatment of migraine because it has which of the following effects? (A) it prevents the release of serotonin (B) it is a \(5-\mathrm{HT}_{1 \mathrm{BRD}}\) agonist (C) it inhibits the COX-2 enzyme (D) it is an antagonist at \(5-\mathrm{HT}_2\) receptors (E) it blocks calcium channels

A 35-year-old woman with a history of migraine reports to her physician that the last time she used her medicine to stop an acute attack, she felt numbness and tingling in her extremities and blanching and cyanosis of her fingers. Which one of the following medications did she take? (A) butorphanol (B) sumatriptan (C) dihydroergotamine (D) tramadol (E) naproxen